Decentralised trials: sponsor checklist for FDA guidance
Decentralised clinical trials can fit Food and Drug Administration requirements when you design them around participant safety, investigator oversight, data reliability, and inspection readiness from the start. If you sponsor these studies, the practical job is to decide which trial activities can move away from the traditional site, who can perform them, and what controls must stay in place to keep the study compliant.
You are not looking for theory. You need a working sponsor checklist that lines up with Food and Drug Administration guidance on remote visits, local healthcare providers, digital health technologies, informed consent, investigational product handling, and source data control. This article gives you that operating view in plain language so you can pressure-test your protocol, vendors, site model, and oversight plan before execution gaps turn into protocol deviations, inspection findings, or unusable data.
What Is The Food And Drug Administration’s Current Guidance On Decentralised Clinical Trials?
The Food and Drug Administration recognizes decentralised clinical trials as trials in which some study activities take place at locations other than the traditional clinical site. That can include telehealth visits, in-home visits, local laboratory testing, assessments by local healthcare providers, remote data capture, and direct distribution of investigational product when the study design supports it. The important point for you as a sponsor is simple: decentralisation changes the operating model, not the underlying regulatory obligations.
You still carry the same responsibility to protect participants, maintain data quality, support investigator oversight, and keep records ready for review. The guidance does not create a lighter path for remote studies. It expects stronger planning, tighter documentation, and more deliberate control over who performs each task, where the task happens, and how study information reaches the investigator and sponsor.
This matters at protocol stage. If your team treats decentralisation as a convenience feature layered onto a standard protocol, you create avoidable failures. A decentralised design affects visit schedules, eligibility checks, delegated duties, medical supervision, investigational product logistics, privacy controls, adverse event escalation, source documentation, vendor oversight, and statistical assumptions tied to missing data and variable assessment settings. See Details…
